Dr. Rosenthal's laboratory has developed an improved mouse model of skin-infection by HSV-1 that exhibits uniform onset and progression of zosteriform lesions. The virulent H129 HSV-1 strain will be used for evaluating selected nanoviricides in this model. The uniform disease onset and progression make it an ideal model for comparative testing of various drug candidates that, the Company believes, can be expected to lead to a broad-spectrum anti-HSV antiviral treatment capable of attacking both HSV-1 and HSV-2.

The Company has developed a library of small chemical ligands that bind to the herpes virus envelope proteins. Using these ligands, a number of candidate nanoviricides that are capable of attacking the herpes virus have been developed. The Company believes that these nanoviricide drug candidates mimic the natural, common attachment function of the body's host cells using which both HSV-1 and HSV-2 cause infection.

"We are very excited about these results," said Eugene Seymour, MD, MPH, CEO of the Company, adding, "We are now one step closer to the development of our anti-Herpes nanoviricide drug."

Source NanoViricides, Inc.